[go: up one dir, main page]

CO4700302A1 - Preparacion de factor recombinante libre de albumina que tiene bajo contenido de azucar - Google Patents

Preparacion de factor recombinante libre de albumina que tiene bajo contenido de azucar

Info

Publication number
CO4700302A1
CO4700302A1 CO97039171A CO97039171A CO4700302A1 CO 4700302 A1 CO4700302 A1 CO 4700302A1 CO 97039171 A CO97039171 A CO 97039171A CO 97039171 A CO97039171 A CO 97039171A CO 4700302 A1 CO4700302 A1 CO 4700302A1
Authority
CO
Colombia
Prior art keywords
preparation
sugar content
low sugar
recombinant factor
free recombinant
Prior art date
Application number
CO97039171A
Other languages
English (en)
Inventor
Nayar Rajiv
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of CO4700302A1 publication Critical patent/CO4700302A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una preparación de rFVIII liofilizada, libre de albúmina,estable que comprende, cuando es reconstruída en agua, aproximadamente65 a 400 mM de glicina,hasta 50 mM de histidina,15 a 60 mM de sucrosa,hasta 50 mM de NaCl,hasta 5 mM de CaCl2 , y50 a 1500 IU rFVIII/ml.Una preparación de rFVIII liofilizada, libre de albúmina, estable que comprende, cuando es reconstruída con agua,290 mM de glicina,20 mM de histidina,30 mM de sucrosa,30 mM de NaCL,2.5 mM de CaCl2 , y50 a 1500 IU rFVIII/ml
CO97039171A 1996-07-12 1997-07-11 Preparacion de factor recombinante libre de albumina que tiene bajo contenido de azucar CO4700302A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/678,492 US5763401A (en) 1996-07-12 1996-07-12 Stabilized albumin-free recombinant factor VIII preparation having a low sugar content

Publications (1)

Publication Number Publication Date
CO4700302A1 true CO4700302A1 (es) 1998-12-29

Family

ID=24723010

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97039171A CO4700302A1 (es) 1996-07-12 1997-07-11 Preparacion de factor recombinante libre de albumina que tiene bajo contenido de azucar

Country Status (30)

Country Link
US (2) US5763401A (es)
EP (1) EP0818204B1 (es)
JP (1) JP4077055B2 (es)
KR (1) KR100491281B1 (es)
CN (1) CN1130224C (es)
AR (1) AR007845A1 (es)
AT (1) ATE191146T1 (es)
AU (1) AU718901B2 (es)
BR (1) BR9704407B1 (es)
CA (1) CA2210038C (es)
CO (1) CO4700302A1 (es)
CZ (1) CZ292183B6 (es)
DE (1) DE69701548T2 (es)
DK (1) DK0818204T3 (es)
ES (1) ES2144293T3 (es)
GR (1) GR3033669T3 (es)
HU (1) HU221415B1 (es)
ID (1) ID19074A (es)
IL (1) IL121273A (es)
MY (1) MY125544A (es)
NZ (1) NZ328297A (es)
PL (1) PL186950B1 (es)
PT (1) PT818204E (es)
RU (1) RU2201252C2 (es)
SG (1) SG50864A1 (es)
SK (1) SK282207B6 (es)
TR (1) TR199700628A2 (es)
TW (1) TW381027B (es)
UA (1) UA43882C2 (es)
ZA (1) ZA976167B (es)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) * 1996-06-26 2009-07-14 Emory University Modified factor VIII
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ES2541470T3 (es) * 1999-02-22 2015-07-20 University Of Connecticut Formulaciones de factor VIII libres de albúmina
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
ATE319424T1 (de) * 1999-12-30 2006-03-15 Intermune Inc Gamma-ifn flüssigtropfenaerosol und verfahren
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
JP2005530683A (ja) * 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体組成物
DE10211227A1 (de) * 2002-03-13 2003-10-02 Aventis Behring Gmbh Verfahren zur Rekonstitution von Iyophilisierten Proteinen
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
CN101912601B (zh) * 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
DE60317822D1 (de) * 2002-10-29 2008-01-10 Alza Corp Stabilisierte feste polypeptidpartikel
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
EP1644030B1 (en) * 2003-07-01 2009-10-28 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
WO2005028496A2 (en) 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
JP2007534633A (ja) * 2003-11-10 2007-11-29 アライバ−プロメティック インコーポレイティド ヒト・アルファ１−抗トリプシン製剤
DK2298287T3 (en) * 2003-12-19 2018-07-23 Novo Nordisk Healthcare Ag Stabilized compositions of factor VII polypeptides
GB0404586D0 (en) * 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
CA2554018A1 (en) * 2004-03-04 2005-09-29 Wyeth Lyophilization method to improve excipient crystallization
ES2347902T3 (es) * 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
EP1750733B1 (en) * 2004-05-03 2013-12-11 Emory University METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
SI1778723T1 (sl) * 2004-08-17 2013-02-28 Regeneron Pharmaceuticals, Inc. Formulacije IL-1 antagonista
ES2434035T3 (es) 2004-12-27 2013-12-13 Baxter International Inc. Conjugados de polímero-factor von Willebrand
NZ561144A (en) * 2005-03-04 2009-09-25 Dynavax Tech Corp Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients
EP1861116B1 (en) 2005-03-25 2015-09-16 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
BRPI0618893A2 (pt) * 2005-11-22 2011-09-13 Wyeth Corp formulações de proteìna de fusão de imunoglobulina
WO2007071068A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
DK1969004T3 (da) 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
DK2364691T3 (da) 2006-06-16 2013-07-01 Regeneron Pharma VEGF antagonist-formuleringer, der kan anvendes til intravitreal administration
RU2324495C1 (ru) * 2006-08-31 2008-05-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения препарата фактора свертывания viii крови человека
ES2655639T3 (es) 2006-12-15 2018-02-21 Baxalta GmbH Conjugado de factor VIIa - ácido (poli)siálico que tiene una semivida in vivo prolongada
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
JP5401446B2 (ja) * 2007-04-26 2014-01-29 バイエル ヘルスケア エルエルシー 凍結貯蔵を目的とした、組み換えタンパク質溶液の安定化
MX2009012964A (es) * 2007-06-01 2010-01-14 Acologix Inc Formulacion de peptido estable a alta temperatura.
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
CA2692165A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
MX2011002316A (es) * 2008-09-03 2011-05-10 Octapharma Ag Nuevas composiciones protectoras para el factor viii producido de manera recombinante.
BRPI0919946A2 (pt) 2008-10-30 2016-02-16 Novo Nordisk As tratamento de diabetes melito usando injeções de insulina com frequência de injeção menor que diariamente
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
MY199187A (en) 2009-06-09 2023-10-19 Prolong Pharmaceuticals Llc Hemoglobin compositions
US10172950B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US10172949B2 (en) 2009-06-09 2019-01-08 Prolong Pharmaceuticals, LLC Hemoglobin compositions
EP2359812A1 (en) 2010-01-18 2011-08-24 Cephalon France Oral lyophilised compositions
HRP20191793T1 (hr) 2010-10-27 2019-12-27 Novo Nordisk A/S Liječenje dijabetesa melitusa injekcijama inzulina koje se primijenjuje u različitim intervalima injiciranja
EP2635297B1 (en) 2010-11-05 2019-02-27 Baxalta GmbH A new variant of antihemophilic factor viii having increased specific activity
JP5943939B2 (ja) * 2010-12-28 2016-07-05 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーＥ．Ｉ．Ｄｕ Ｐｏｎｔ Ｄｅ Ｎｅｍｏｕｒｓ Ａｎｄ Ｃｏｍｐａｎｙ フッ素化ポリエステルブレンド糸から製造される布帛
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CN102430116A (zh) * 2011-08-19 2012-05-02 上海新兴医药股份有限公司 用于人凝血因子ⅷ制剂的干热处理方法及其稳定剂
ES2776195T3 (es) 2013-03-15 2020-07-29 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
WO2014152530A1 (en) 2013-03-15 2014-09-25 Bayer Healthcare Llc Variant factor viii polypeptides and methods of their production and use
BR112015022730A2 (pt) * 2013-03-15 2017-10-31 Bayer Healthcare Llc formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
JP2017509659A (ja) * 2014-04-01 2017-04-06 アドヴァンテック・バイオサイエンス・ファルマスーティカ・リミターダ 低糖−低グリシンの安定な第ｖｉｉｉ因子製剤
JP2017509658A (ja) 2014-04-01 2017-04-06 アドヴァンテック・バイオサイエンス・ファルマスーティカ・リミターダ カルシウム添加剤を使用しない第ｖｉｉｉ因子の安定化
MX375557B (es) 2014-07-18 2025-03-06 Sanofi Sa Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer.
EP3177317B1 (en) * 2014-08-04 2020-03-18 CSL Limited Factor viii formulation
US10568948B2 (en) 2015-05-13 2020-02-25 Agenus Inc. Vaccines for treatment and prevention of cancer
BR112018008319A2 (pt) * 2015-11-05 2018-10-30 Novo Nordisk A/S formulação de fviii
CN106139127B (zh) * 2016-08-05 2020-04-07 无锡药明生物技术股份有限公司 重组凝血因子ⅷ冻干制剂
JP2021522239A (ja) 2018-04-26 2021-08-30 アジェナス インコーポレイテッド 熱ショックタンパク質結合ペプチド組成物およびその使用方法
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US20220389082A1 (en) 2019-07-04 2022-12-08 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
WO2022099223A2 (en) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440679A (en) * 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4623717A (en) * 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4847362A (en) * 1985-02-01 1989-07-11 New York University Method for purifying antihemophilic factor
US4758657A (en) * 1985-07-11 1988-07-19 Armour Pharmaceutical Company Method of purifying Factor VIII:C
CA1329760C (en) * 1987-10-29 1994-05-24 Ted C. K. Lee Plasma and recombinant protein formulations in high ionic strength media
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
EP0638091B1 (en) * 1992-04-30 2005-12-07 Probitas Pharma Inc. Improved solubilization and stabilization of factor viii complex
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
JP3905921B2 (ja) * 1992-10-02 2007-04-18 ジェネティクス インスチチュート リミテッド ライアビリティー カンパニー 凝固第▲ｖｉｉｉ▼因子を含む組成物及びその製造方法並びに安定剤としての界面活性剤の使用方法
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content

Also Published As

Publication number Publication date
HU221415B1 (en) 2002-09-28
EP0818204A3 (en) 1998-02-04
TW381027B (en) 2000-02-01
SK282207B6 (sk) 2001-12-03
CA2210038A1 (en) 1998-01-12
BR9704407A (pt) 2000-06-06
HU9701191D0 (en) 1997-08-28
MY125544A (en) 2006-08-30
KR980008241A (ko) 1998-04-30
PL321058A1 (en) 1998-01-19
EP0818204A2 (en) 1998-01-14
CN1181974A (zh) 1998-05-20
UA43882C2 (uk) 2002-01-15
AU2860497A (en) 1998-01-22
DE69701548T2 (de) 2000-07-27
HUP9701191A2 (hu) 1999-06-28
TR199700628A2 (xx) 1998-01-21
MX9705209A (es) 1998-05-31
JPH1067679A (ja) 1998-03-10
SG50864A1 (en) 1998-07-20
AR007845A1 (es) 1999-11-24
NZ328297A (en) 1999-09-29
US5874408A (en) 1999-02-23
HUP9701191A3 (en) 2000-08-28
IL121273A (en) 2000-09-28
CN1130224C (zh) 2003-12-10
CZ292183B6 (cs) 2003-08-13
CA2210038C (en) 2007-03-13
ZA976167B (en) 1998-02-02
ES2144293T3 (es) 2000-06-01
CZ219497A3 (cs) 1998-01-14
AU718901B2 (en) 2000-04-20
IL121273A0 (en) 1998-01-04
KR100491281B1 (ko) 2005-08-05
RU2201252C2 (ru) 2003-03-27
PT818204E (pt) 2000-08-31
ATE191146T1 (de) 2000-04-15
JP4077055B2 (ja) 2008-04-16
US5763401A (en) 1998-06-09
GR3033669T3 (en) 2000-10-31
DK0818204T3 (da) 2000-07-17
ID19074A (id) 1998-06-11
SK92197A3 (en) 1998-02-04
BR9704407B1 (pt) 2010-03-09
EP0818204B1 (en) 2000-03-29
PL186950B1 (pl) 2004-04-30
DE69701548D1 (de) 2000-05-04

Similar Documents

Publication Publication Date Title
CO4700302A1 (es) Preparacion de factor recombinante libre de albumina que tiene bajo contenido de azucar
RU97111733A (ru) Устойчивая, свободная от альбумина лиофилизованная композиция рекомбинантного фактора viii
EE04481B1 (et) Peptiididel ja adjuvantidel baseeruv farmatseutiline kompositsioon immuunmodulatsiooni jaoks
IL142216A0 (en) A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same
EP0950665A4 (en) PHYSIOLOGICALLY ACTIVE MODIFIED PROTEINS AND DRUG COMPOSITIONS CONTAINING THEM
DE69428521D1 (de) Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
DOP2001000197A (es) Interleuquina-2 estabilizada
GR3030146T3 (en) Stable lyophilized formulation containing a protein and dosage kit.
ES8704350A1 (es) Procedimiento para la preparacion de un conjugado bacteriano
UA70296A (uk) Фармацевтична композиція, що містить ліофілізовані ліпосоми, які енкапсулюють активний інгредієнт з високим ступенем нерозчинності у воді, і спосіб одержання вказаної композиції
DE3875108D1 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
EP0422125A4 (en) Platelet blocking peptides
IL84484A0 (en) T-cell suppressor protein in pure form,its preparation by recombinant methods and pharmaceutical compositions containing it
TR199902575T2 (xx) Peptitler, proteinler ve nükleik asitler için stabil farmasötik uygulama formu.
IT1290817B1 (it) Composizione edulcorante solubile contenente fibre alimentari sua preparazione ed uso a scopo alimentare
CO5050337A1 (es) Composiciones farmaceuticas que incluyen polipeptidos il-18 y preparacion de la misma
GB9726343D0 (en) The use of excipients to accelerate freeze-drying
EP1015553A4 (en) RECOMBINANT bHLH-PAS / JHR POLYPEPTIDE AND METHOD OF USE THEREOF FOR THE SELECTION OF POTENTIAL INSECTICIDES
ATE215361T1 (de) Liposomen mit mehrfach verzweigten peptidkonstruktionen zur verwendung gegen hiv
NZ219192A (en) Peptides related to p97 melanoma-associated peptide, recombinant virus and vaccines
FR2629785B1 (fr) Embarcation legere de randonnee comportant des couchettes pivotables et une tente
EE9900178A (et) Interleukiin-1ß konverteeriva ensüümiga seonduv peptiid, selle kasutamine ja farmatseutiline kompositsioon
BR7601302U (pt) Disposiçao construtiva em envelope com lacre
TR28011A (tr) Aritilmis/saf streptogramin ve hazirlanisi.
ATE81531T1 (de) Biologisch aktive peptide tan-866.